McDonald's is a big company that sells burgers and fries. They are expected to make more money in the future. Merck is another company that makes medicine. Some people on TV talked about these companies and said they might be good to buy. The price of McDonald's stock went down a little bit, but it's still expensive. Read from source...

1. The title is misleading and exaggerated. It implies that McDonald's revenues will increase significantly, but does not provide any evidence or data to support this claim. A more accurate title would be "McDonald's Revenues Expected To Increase Slightly, Plus Merck And More On CNBC's 'Final Trades'"
2. The article mentions a legal action by GAR against the BDS Malaysia movement, but does not explain what this is about or how it affects McDonald's revenues. This information is irrelevant and distracting from the main topic of the article, which is the financial performance of McDonald's and Merck.
3. The article cites HSBC analyst Meredith Jensen as a source for its bullish outlook on McDonald's, but does not disclose any potential conflicts of interest or the methodology behind her price target calculation. This raises doubts about the credibility and reliability of her opinion.
4. The article also cites Bryn Talkington of Requisite Capital Management as a source for his recommendation of Pacer US Cash Cows 100 ETF, but does not mention any track record or performance history of this fund. This makes it difficult to evaluate the quality and suitability of his advice.
5. The article ends with an unrelated advertisement for another Benzinga publication, which is inappropriate and detracts from the main purpose of the article, which is to inform readers about McDonald's and Merck's latest developments.

The article provides an overview of the expected increase in McDonald's revenues, as well as some insights from analysts and traders regarding other stocks and ETFs that may be worth considering. Based on this information, I suggest the following investment strategies:

- For aggressive growth seekers, Merck & Co (NYMC) is a promising option with a Buy rating from HSBC analyst Meredith Jensen and a potential price target of $317. The stock has shown consistent performance and could benefit from positive developments in the pharmaceutical industry. However, there are also risks involved, such as regulatory hurdles, competition, and legal issues. Investors should monitor the news closely and be prepared to adjust their positions accordingly.
- For conservative investors looking for steady income, Pacer US Cash Cows 100 ETF (BOSS) may offer a compelling opportunity with a free cash flow yield of around 9%. This ETF tracks the performance of companies that generate high amounts of free cash flow and pays quarterly distributions. However, there are also challenges ahead, such as rising interest rates, inflation, and market volatility. Investors should diversify their portfolios and consider holding this ETF for the long term.
- For value hunters seeking a turnaround play, McDonald's Corporation (MCD) could be an attractive option despite its recent decline. The stock has strong fundamentals, a loyal customer base, and a global presence. Additionally, GAR, the licensee of McDonald's in Malaysia, is taking legal action against BDS Malaysia movement, which may help boost the brand's image and sales. However, there are also risks involved, such as changing consumer preferences, increased competition, and operational challenges. Investors should conduct thorough research and wait for a better entry point before buying this stock.